Grammatical mood

Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health

Retrieved on: 
Tuesday, January 17, 2023
Neuronetics, The Journal of Clinical Psychiatry, TMS, Depression, Anxiety, Quality of life, FDA, GAD-7, MDD, Marketing, Patient, Grammatical mood, Journal, Research, STIM, Pharmaceutical industry

These 1,800 patients were treated with NeuroStar TMS in commercial clinics and represented a diversity of patients with MDD and moderate-to-severe anxiety symptoms.

Key Points: 
  • These 1,800 patients were treated with NeuroStar TMS in commercial clinics and represented a diversity of patients with MDD and moderate-to-severe anxiety symptoms.
  • Patients with anxious depression exhibited clinically meaningful anxiety symptom improvement and antidepressant effects.
  • “These results are impressive because they further illustrate the mental health benefits that NeuroStar TMS can provide for many patients with psychiatric disorders like anxious depression.
  • Having access to this large registry allows us to further the research and establish best practices for treating physicians.”
    Neuronetics received FDA clearance to treat anxious depression with NeuroStar Advanced Therapy in July 2022.

Consumers Turning to Credit Cards and Payday Loans to Cover Costs of Living, with Debt-Stress Impacting Mental Health, Self-Esteem & More – 10th Annual BC Consumer Debt Study

Retrieved on: 
Monday, January 16, 2023
Mental health, Depression, Anxiety, Suicide, Helpless (2012 film), Grammatical mood, COVID-19, Credit, Security (finance), Bank

VANCOUVER, British Columbia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- BC Licensed Insolvency Trustees Sands & Associates released complete findings from their 2022 BC Consumer Debt Study today, marking the 10th annual study in this unique series that aims to highlight consumer debt problems and the financial challenges British Columbians face.

Key Points: 
  • Credit card debt a problem for nearly 3 in 5 individuals polled in the 2022 BC Consumer Debt Study, and worrying high-cost payday loan use is on the rise.
  • Most troubling - almost 4 in 5 people said their mental health suffered being in debt.
  • VANCOUVER, British Columbia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- BC Licensed Insolvency Trustees Sands & Associates released complete findings from their 2022 BC Consumer Debt Study today, marking the 10th annual study in this unique series that aims to highlight consumer debt problems and the financial challenges British Columbians face.
  • As high-cost credit dominated debt-loads, 2022 BC Consumer Debt Study also highlights troubling findings as to common causes of what ultimately became problem debt.

Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023

Retrieved on: 
Monday, January 9, 2023
OLE, Ageing, SCN8A, Depression, Seizure, Icahn School of Medicine at Mount Sinai, Safety, FDA, FOS, MADRS, MPC, MDD, NDA, Grammatical mood, DBP, EPIK, Patient, Neurocrine Biosciences, Epilepsy, MRI, KCNQ2, Anhedonia, Magnetic resonance, Neurocrine, Mount Sinai, Medical imaging, Pharmaceutical industry, Xenon

BURNABY, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined recent progress in its clinical programs and key milestones for 2023.

Key Points: 
  • BURNABY, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined recent progress in its clinical programs and key milestones for 2023.
  • Xenon has initiated a Phase 3 clinical trial, called X-ACKT, to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic clonic seizures (PGTCS).
  • The primary efficacy endpoint is the MPC in monthly PGTCS frequency from baseline through the DBP of XEN1101 compared to placebo.
  • Pursuant to the terms of the agreement, Xenon has the potential to receive certain clinical, regulatory, and commercial milestone payments, as well as future sales royalties.

Los Angeles Gateways Hospital and Mental Health Center Becomes the Largest Provider of Acute Care for Adolescent Mental Health and Substance Use Disorder in Los Angeles County

Retrieved on: 
Monday, January 9, 2023
California Department of Health Care Services, Mental health, Intersex, United States Public Health Service, Restoration Gateway Hospital, Bed, Echo Park, Suicide, Child, CDC, COVID-19, Death, Adolescence, Centers for Disease Control and Prevention, Elgin Mental Health Center, Face, Patient, Transitional age youth, Pressure, DHCS, Topical steroid withdrawal, Grammatical mood, Sadness, TAY, Substance abuse, Medicine

LOS ANGELES, Jan. 9, 2023 /PRNewswire/ -- On the heels of Governor Gavin Newsom's announcement to award $480.5 million in grants for 54 projects to improve California's behavioral health infrastructure for children and youth, Los Angeles-based Gateways Hospital and Mental Health Center announced that it will receive $19.2 million of the grant funding to expand behavioral and mental health services for adolescents at its facilities at its Echo Park hospital campus. The expansion and grant are part of the Los Angeles County-based projects that support behavioral health infrastructure to address gaps in care and create sustainable improvements that better serve county residents. The expansion will also make Gateways Hospital the largest provider of acute adolescent (ages 13-18) mental health and substance use disorder in Los Angeles County.

Key Points: 
  • The expansion will also make Gateways Hospital the largest provider of acute adolescent (ages 13-18) mental health and substance use disorder in Los Angeles County.
  • "The investment in behavioral and mental health services tailored to youth comes at a pivotal time," said Gateways Hospital CEO Dr. Phil Wong.
  • We commend Governor Newsom and Los Angeles County for prioritizing the funds to focus on youth mental health by expanding infrastructure capacity to help shift the tide.
  • The awards are delivered through the Department of Health Care Services (DHCS) Behavioral Health Continuum Infrastructure Program (BHCIP) Round 4: Children and Youth grants.

Total Life Releases "Kick Depression" Program Designed for Aging Adults

Retrieved on: 
Monday, December 19, 2022
KFF, Mental health, Anxiety, United States Public Health Service, CBT, Cognitive behavioral therapy, Depression, Lethargy, Patient, Growing (band), Total Life Forever, Insurance, SAMHSA, Topical steroid withdrawal, Grammatical mood, Ageing, Medicare, Health insurance, Medicine

These can be exacerbated in aging people, as depression affects older adults differently.

Key Points: 
  • These can be exacerbated in aging people, as depression affects older adults differently.
  • Total Life matches patients with a dedicated licensed counselor who will help work through difficult feelings and achieve mental health and life goals.
  • Using proven techniques of psychoeducation and skill building activities, the team at Total Life helps patients challenge and overcome depression symptoms.
  • Total Life provides mental health therapy and counseling online or by phone for older adults.

EQS-News: Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer

Retrieved on: 
Sunday, January 22, 2023
Psilocybin, Cancer, Mood disorder, Mental health, Anxiety, Commercial, Biotechnology, Innes, Learned helplessness, Research, Addiction medicine, Depression, Orexo, Series, CNS, Growth, Patient, Novartis, Psychotherapy, Demoralization, Grammatical mood, Chairperson, Senior, Pharmaceutical industry

New York, NY, January 5, 2023 - Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Key Points: 
  • New York, NY, January 5, 2023 - Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
  • Innes Meldrum has nearly 30 years of global experience in the biotechnology and technology industries, having most recently served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.
  • “We are delighted to have Innes join Reset Pharma as CEO,” said Philip Taub, Chair of the Board.
  • I warmly welcome Innes and look forward to working with him and the entire Reset Pharma team.

Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program

Retrieved on: 
Thursday, January 5, 2023
Anxiety, Advertising, Pain, Food, FM, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Grammatical mood, Patient, Safety, FDA, Fatigue, Conditional sentence, Fibromyalgia, Pharmaceutical industry

At this meeting, the Company will discuss with the FDA plans for a Phase 3 program that would support submission of a new drug application for IMC-1 for the treatment of FM.

Key Points: 
  • At this meeting, the Company will discuss with the FDA plans for a Phase 3 program that would support submission of a new drug application for IMC-1 for the treatment of FM.
  • The Company plans to provide a program update by the end of April following the receipt of formal written feedback from the FDA.
  • “New” patients treated with IMC-1 also exhibited a lower discontinuation rate due to adverse events as compared with “new” patients receiving] placebo.
  • All patients treated with IMC-1 demonstrated exemplary safety and tolerability in the FORTRESS study.

Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer

Retrieved on: 
Thursday, January 5, 2023
Psilocybin, Cancer, Mood disorder, Mental health, Anxiety, Commercial, Biotechnology, Innes, Learned helplessness, Research, Addiction medicine, Depression, Orexo, Series, CNS, Growth, Patient, Novartis, Psychotherapy, Demoralization, Grammatical mood, Chairperson, Senior, Pharmaceutical industry

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Key Points: 
  • NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
  • Innes Meldrum has nearly 30 years of global experience in the biotechnology and technology industries, having most recently served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.
  • “We are delighted to have Innes join Reset Pharma as CEO,” said Philip Taub, Chair of the Board.
  • I warmly welcome Innes and look forward to working with him and the entire Reset Pharma team.

Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Sunday, January 8, 2023
Biotechnology, Pharmaceutical, Health, PD, PDUFA, NEST, MDD, Therapy, GABAA receptor, Depression, NDA, Grammatical mood, Disease, Patient, GABAA, HD, FDA, Postpartum depression, Cognition, PPD, Huntington's disease, Conference, Zuranolone, PAM, NMDA, Neuropsychiatry, AD, New Drug Application, Pharmaceutical industry, Medical device, Biogen, Sage

As part of this presentation, Mr. Greene will provide key updates on programs across Sage’s depression, neuropsychiatry and neurology portfolios.

Key Points: 
  • As part of this presentation, Mr. Greene will provide key updates on programs across Sage’s depression, neuropsychiatry and neurology portfolios.
  • Dysfunction in these systems is thought to be at the core of numerous neurological and neuropsychiatric disorders.
  • Sage expects these efforts and other permitted pre-launch activities to continue to broaden and ramp up in the coming year.
  • Sage continues to advance a robust clinical program for SAGE-718, the Company’s first-in-class NMDA receptor PAM and lead neuropsychiatric drug candidate.

Better Thinking: A Thoughtful Last-Minute Gift

Retrieved on: 
Monday, December 19, 2022
Posit Science Corporation, Computer, Gait, Friends, Algorithm, Memory, Holiday, Grammatical mood, SAN, Tablet, Attention, Safety, Suggestion, Cognition, Athlete, Quality of life, Hearing, Mobile phone, Mail order

A suggestion that comes from the neuroscience company Posit Science is its brain health and fitness program, BrainHQ .

Key Points: 
  • A suggestion that comes from the neuroscience company Posit Science is its brain health and fitness program, BrainHQ .
  • The gift of better brain health and performance is good for everyone.
  • Gift shoppers can get special holiday deals with online delivery of BrainHQ gift subscriptions (by email) up to and including Christmas Day at this special page of the BrainHQ site.
  • Vouchers for the classes, which help new users with BrainHQ (and with other aspects of pursuing better brain health), can be purchased at an introductory price (in combination with one-year gift subscriptions), here.